Bul, M.

cancer prostate screening prostate cancer study biopsy patient surveillance mortality result treatment follow-up erspc disease outcome trial interval group gleason death diagnosis roobol roobol mj score number european randomized study antigen rotterdam randomized european cohort value survival control arm prostate-specific antigen volume detection stage analysis schroder fh prostatectomy tumor chapter table control characteristic reduction incidence prostate-specific schroder disease-specific therapy criteria reclassification population level effect gleason score pca mortality strategy management progression biopsy cores screen-detected psa-dt escape figure oncol pc-speci fic mortality program protocol screening arm factor overdiagnosi psa-d risk prostate cancer prediction bangma ch steyerberg ew sextant